Background/Aims/Objectives: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has detrimental effects on the quality of life including the aspect of sexual dysfunction. The aim of the study was to identify if there was an adverse effect on the male genital compartment and if there are systemic or compartment-specific local signals for epigenetic dysregulation of inflammatory factors in CP/CPPS patients. Methods: One hundred five NIH IIIb CP/CPPS patients and 41 healthy men were recruited and underwent investigations of urines, semen and blood. Promoter methylation and expression of the chemokine C-X-C motif chemokine 12 and its receptor C-X-C chemokine receptor type 4 (CXCR4) (involved in the recruitment of mast cells) were analyzed in prostate epithelial cell lines and in healthy volunteers' and patients' blood, ejaculate cell pellets, and separated ejaculate fractions (sperm and seminal somatic cells). Results: Independently from age, CP/CPPS NIH IIIb was associated with significant impairment of sperm motility, morphology and semen pH (p < 0.001). Patients older than 33 years showed significantly increased seminal interleukin-8 and serum prostate specific antigen values. In patients, the CXCR4 mRNA-expression was significantly decreased in whole blood and ejaculate cell pellets due to promoter hypermethylation. Analyses on separated fractions of sperm and seminal somatic cells revealed that sperm DNA was unaffected, whereas somatic cell DNA was differentially methylated. Conclusions: NIH IIIb CP/CPPS has negative effects on surrogate parameters of male fertility and is associated significantly with systemic and local epigenetic inactivation of CXCR4.

Keywords:
Subfertility, Chronic prostatitis, Epigenetic gene inactivation, C-X-C chemokine receptor type 4, C-X-C motif chemokine 12
1.
Wagenlehner F, Pilatz A, Linn T, Diemer T, Schuppe HC, Schagdarsurengin U, et al: Prostatitis and andrological implications. Minerva Urol Nefrol 2013;65:117-123.
2.
Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-237.
3.
Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, et al: Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol 2010;184:2339-2345.
4.
World Health Organisation: WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. New York, Cambridge University Press, 1993.
5.
Rusz A, Pilatz A, Wagenlehner F, Linn T, Diemer T, Schuppe HC, et al: Influence of urogenital infections and inflammation on semen quality and male fertility. World J Urol 2012;30:23-30.
6.
Shang Y, Liu C, Cui D, Han G, Yi S: The effect of chronic bacterial prostatitis on semen quality in adult men: a meta-analysis of case-control studies. Sci Rep 2014;4:7233.
7.
Henkel R, Ludwig M, Schuppe HC, Diemer T, Schill WB, Weidner W: Chronic pelvic pain syndrome/chronic prostatitis affect the acrosome reaction in human spermatozoa. World J Urol 2006;24:39-44.
8.
Marjoram L, Alvers A, Deerhake ME, Bagwell J, Mankiewicz J, Cocchiaro JL, et al: Epigenetic control of intestinal barrier function and inflammation in zebrafish. Proc Natl Acad Sci U S A 2015;112:2770-2775.
9.
Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al: Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015;525:389-393.
10.
Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120.
11.
Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-1109.
12.
Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW: Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci U S A 1999;96:5215-5220.
13.
Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G: The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1alpha acts as a mast cell chemotaxin. Eur J Immunol 2000;30:3614-3622.
14.
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010;29:709-722.
15.
Li Y, Chen M, Yuan J, Zhou X, He W, Zu X, et al: CXCR4 expression in bladder transitional cell carcinoma and its relationship with clinicopathological features. Urol Int 2014;92:157-163.
16.
Gonzalez EJ, Arms L, Vizzard MA: The role(s) of cytokines/chemokines in urinary bladder inflammation and dysfunction. Biomed Res Int 2014;2014:120525.
17.
Lotti F, Corona G, Mondaini N, Maseroli E, Rossi M, Filimberti E, et al: Seminal, clinical and colour-Doppler ultrasound correlations of prostatitis-like symptoms in males of infertile couples. Andrology 2014;2:30-41.
18.
Nickel JC, Nyberg LM, Hennenfent M: Research guidelines for chronic prostatitis: consensus report from the first national institutes of health international prostatitis collaborative network. Urology 1999;54:229-233.
19.
Schaeffer AJ, Datta NS, Fowler JE Jr, Krieger JN, Litwin MS, Nadler RB, et al: Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Urology 2002;60(6 suppl):1-4.
20.
Weidner W, Naber KG: [Prostatitis syndrome: consensus of the 6th International Consultation in Paris, 2005]. Aktuelle Urol 2006;37:269-271.
21.
Hochreiter W, Ludwig M, Weidner W, Wagenlehner F, Naber K, Eremenco S, et al: [National institutes of health (NIH) chronic prostatitis symptom index. The German version]. Urologe A 2001;40:16-17.
22.
Pilatz A, Hossain H, Kaiser R, Mankertz A, Schuttler CG, Domann E, et al: Acute epididymitis revisited: impact of molecular diagnostics on etiology and contemporary guideline recommendations. Eur Urol 2015;68(3):428-35.
23.
Xiao J, Ren L, Lv H, Ding Q, Lou S, Zhang W, et al: Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a case-control study. Urol Int 2013;91:410-416.
24.
WHO: WHO Laboratory Manual for the Examination and Processing of Human Semen. Geneva, 2010.
25.
Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, et al: A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. J Pathol 2014;234:86-98.
26.
Lenhard B, Sandelin A, Carninci P: Metazoan promoters: emerging characteristics and insights into transcriptional regulation. Nat Rev Genet 2012;13:233-245.
27.
Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, et al: National institutes of health chronic prostatitis symptom index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2013;63:953-959.
28.
Shoskes DA, Nickel JC, Dolinga R, Prots D: Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 2009;73:538-542; discussion 542-543.
29.
Magri V, Marras E, Restelli A, Wagenlehner FM, Perletti G: Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015;9:658-666.
30.
Krieger JN, Ross SO, Penson DF, Riley DE: Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Urology 2002;60:959-963.
31.
Punab M, Kullisaar T, Mandar R: Male infertility workup needs additional testing of expressed prostatic secretion and/or post-massage urine. PLoS One 2013;8:e82776.
32.
Murphy SF, Schaeffer AJ, Thumbikat P: Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol 2014;11:259-269.
33.
Roman K, Done JD, Schaeffer AJ, Murphy SF, Thumbikat P: Tryptase-PAR2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome. Pain 2014;155:1328-1338.
34.
Wolff H: The biologic significance of white blood cells in semen. Fertil Steril 1995;63:1143-1157.
35.
Done JD, Rudick CN, Quick ML, Schaeffer AJ, Thumbikat P: Role of mast cells in male chronic pelvic pain. J Urol 2012;187:1473-1482.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.